Cascadia Advisory Services’s Pfizer PFE Stock Holding History

Cascadia Advisory Services’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$363K	Buy	+9,779	New	+$348K	0.1%	161

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cascadia Advisory Services's PFE Position: Q4 2019 in Review

Cascadia Advisory Services opened a new position in Pfizer (PFE) in Q4 2019: 9,779 shares worth $363K. The stake represents 0.1% of the portfolio and ranks #161 among its holdings.

2,525 funds tracked by Wall St. Rank hold PFE as of Q4 2019.

Cascadia Advisory Services held 9,779 shares of Pfizer worth $363K as of Q4 2019.
Pfizer was a new Cascadia Advisory Services position in Q4 2019.
Pfizer made up 0.1% of Cascadia Advisory Services's portfolio in Q4 2019, its #161 holding.
2,525 funds tracked by Wall St. Rank held Pfizer as of Q4 2019.

Based on Cascadia Advisory Services's 13F filing for Q4 2019, filed 11 Feb 2020.